Value Investors: Buy Canada’s Best Pharmaceutical Stock

CRH Medical Corporation (TSX:CRH) could become a market leader in the gastrointestinal business. Investors could still purchase the stock, as higher acquisition offers than the one recently made are likely.

| More on:

CRH Medical (TSX:CRH) is a North American company focused on providing physicians throughout the United States with innovative products and services for the treatment of gastrointestinal (GI) diseases. The company distributes the CRH O’Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to gastroenterology practices, creating meaningful relationships with the gastroenterologists it serves.

A few days back, WELL Health Technologies (TSX:WELL) recently announced a deal to acquire CRH for $369.2 million. This is expected to be a wonderful acquisition for WELL Health, which is raising equity from several high-profile investors, including Mr. Li Ka-shing, Hong Kong’s most famous business tycoon, to fund the purchase. WELL Health is expected to raise equity at a 25% premium to the volume weighted average price due to significant investor demand.

At the acquisition price, CRH is valued a price-to-earnings ratio of 97.60, price-to-book ratio of 4.83, and market capitalization of $349 million. Debt is very sparingly used at CRH, as evidenced by a debt-to-equity ratio of just 0.96. Prior to the takeover offer, CRH reported depressed performance metrics with an operating margin of (7.95)% and a return on equity of (2.6)%.

The CRH O’Regan System is a single-use, disposable, hemorrhoid banding technology that is safe and highly effective in treating all grades of hemorrhoids. In 2014, CRH acquired Gastroenterology Anesthesia Associates (GAA), a full-service gastroenterology anesthesia company that provides anesthesia services for patients undergoing endoscopic procedures. Performing these procedures under anesthetic provides more comfort for patients. CRH has continued to leverage the capabilities it acquired through GAA to consolidate the highly fragmented gastroenterology anesthesia provider business.

CRH’s goal is to establish itself as the premier provider of innovative products and essential services to gastroenterologists. The company has been on a shopping spree over the last five years, buying up anesthesia services providers in the United States. Most recently, CRH acquired 100% of certain assets of Anesthesia Care Associates, an anesthesia services provider in Indiana.

The company’s management, medical and support teams have developed specific skills and knowledge in the United States (U.S.) healthcare market. The extent and breadth of CRH’s experience delivering healthcare services, developed through years of operating across multiple U.S. states, have provided it with a national scope of knowledge that is not easily acquired or replicated.

CRH’s management has acquired the knowledge necessary to gather and process the critical information required to enter prospective markets. The company has developed this knowledge and expertise by acquiring new personnel with the requisite skill sets.

CRH outsources design and manufacturing activities to save on costs. However, the company maintains direct control over customer service activities to ensure that it provides the best service to customers. Through an established system of customer feedback, CRH monitors for signs of quality problems and customer issues. CRH has also established a feedback system to provide early warning of quality problems and to determine whether it has met the customer’s requirements.

In summary, CRH could become a market leader in the gastrointestinal business which could result in a significantly higher stock price. Investors could still purchase the stock, as higher acquisition offers than the one made by WELL Health are likely.

Fool contributor Nikhil Kumar has no position in any of the stocks mentioned. The Motley Fool owns shares of CRH Medical.

More on Investing

a man relaxes with his feet on a pile of books
Dividend Stocks

How to Use Your TFSA to Average $2400 Per Year in Tax-Free Passive Income

Income-seeking investors should consider these picks to build a tax-free passive portfolio with some of the best Canadian dividend stocks…

Read more »

man in suit looks at a computer with an anxious expression
Dividend Stocks

Where I’d Put $10,000 in Canadian Stocks Right Now

A $10,000 market position spread across three reliable dividend payers is a strategic shield against ongoing volatility.

Read more »

chart reflected in eyeglass lenses
Energy Stocks

1 Undervalued Canadian Stock Quietly Gearing Up for 2026

Let's dive into why Suncor (TSX:SU) looks like one of the top no-brainer picks for investors looking for a mix…

Read more »

Person holds banknotes of Canadian dollars
Dividend Stocks

The Best Stocks to Invest $1,000 in Right Now

These top stocks combine diversification, durable business models, and long-term wealth-building potential for patient investors.

Read more »

A worker overlooks an oil refinery plant.
Dividend Stocks

3 Canadian Stocks Perfectly Positioned for the Infrastructure Boom

These Canadian infrastructure stocks have reliable dividends and solid long-term growth potential, making them top picks in today's market.

Read more »

Blocks conceptualizing the Registered Retirement Savings Plan
Dividend Stocks

A Better Way to Invest Your RRSP Refund in 2026

The RRSP tax refund is a welcome windfall but can offset taxes further through income and growth investing.

Read more »

doctor uses telehealth
Tech Stocks

1 Growth Stock Set to Skyrocket in 2026 and Beyond

Well Health Technologies continues to experience rapid growth, with rising profitability and cash flows set to take the stock higher.

Read more »

pig shows concept of sustainable investing
Investing

The Ideal Canadian Stocks to Buy and Hold Forever in a TFSA

Considering their quality asset bases, robust cash flows, disciplined capital allocation, and consistent dividend growth, these two Canadian stocks are…

Read more »